The full name of biopharmaceutical biotech drugs, broadly refers to all kinds of bioactive substances based on biomass and their synthetic analogues, as well as drugs made by modern biotechnology. Narrow sense refers to the use of organisms, biological tissues, cells and their components to comprehensively apply the principles and technical methods of chemistry, biology and medicine to prevent, diagnose, treat and rehabilitate health products. DNA recombination technology or other protein or nucleic acid drugs developed by modern biotechnology.
Biotechnology drugs are important carriers of the bio-economy. It can treat diseases, biotechnology drugs including cell pellets, recombinant protein drugs, antibodies, vaccines and oligonucleotide drugs, etc., mainly for the prevention and treatment of cancer, cardiovascular diseases, infectious diseases, asthma, diabetes, genetic diseases, cardiovascular and cerebrovascular diseases. Difficult diseases such as rheumatoid arthritis have been widely used in clinical practice, bringing revolutionary changes to the pharmaceutical industry.
Since biopharmaceuticals are naturally occurring proteins or polypeptides of human beings, the amount is small and the activity is strong, and the amount of the biopharmaceuticals is extremely small, which has a significant effect, and relatively less side effects, lower toxicity, and higher safety. Biotechnology active protein or peptide drugs are unstable, apt to be degraded, easily inactivated, and easily damaged by microbial contamination and enzymatic hydrolysis.
In view of the above various strict storage conditions, biopharmaceuticals require low adsorption, no reaction with metal ions, low temperature resistance (liquid nitrogen environment), high temperature resistance, and some drugs belong to interferon alkaline, so COP (cycloolefin) Polymers) are the main packaging materials for biopharmaceuticals. Since the 13th Five-Year Plan, the state has advocated vigorous development of biopharmaceutical original research drugs and generic drugs. COP as a mainstream packaging material for biopharmaceuticals in foreign countries is still in its infancy in the country. With the continuous improvement of biopharmaceutical technology, COP will be the mainstream. Packaging materials, enter the pharmaceutical packaging market.
Copyright © Shijiazhuang Xinfuda Medical Packaging Co., Ltd. All Rights
MAKE AN ENQUIRY
